- Kincell Bio, a US cell therapy CDMO, has partnered with Seattle-based Moonlight Bio to provide CMC development and GMP manufacturing services for Moonlight’s lead T cell therapy.
- The collaboration aims to accelerate clinical supply, support process and analytical transfer, and advance Moonlight’s therapy into clinical trials for solid tumors.
Kincell Bio, a US-based cell therapy CDMO, has announced a partnership with Moonlight Bio, Inc., a Seattle biotech company focused on T cell therapies for solid tumors. The agreement covers process and analytical transfer, as well as GMP manufacturing to support the scale-up and clinical supply of Moonlight’s lead T cell therapy product.
The collaboration is intended to accelerate clinical supply and help meet patient needs. It leverages Kincell Bio’s capabilities in CMC development, early and late-stage clinical, and commercial cGMP manufacturing.
“At Moonlight, we are dedicated to delivering T cell therapies that address barriers obstructing successful outcomes in solid tumors – the vast majority of the global cancer disease burden. We are very excited to collaborate with Kincell to advance our lead program into the clinic.”
Jordan Jarjour, PhD, Moonlight’s CSO.
Bruce Thompson, PhD, added: “I am excited to partner with the team at Moonlight as they develop an innovative cell therapy that has the potential to make a significant impact on patient disease burden. Kincell has a strong and agile team that thrives on finding technical solutions to deliver for our clients and their patients.”
Kincell Bio provides tailored solutions across process and analytical development and clinical GMP manufacturing, supporting biotech and pharmaceutical companies in bringing cell therapies to market efficiently.
